Literature DB >> 21739480

Potentially functional polymorphisms in DNA repair genes and non-small-cell lung cancer survival: a pathway-based analysis.

Jing Dong1, Zhibin Hu, Yongqian Shu, Shiyang Pan, Wenping Chen, Yi Wang, Lingmin Hu, Yue Jiang, Juncheng Dai, Hongxia Ma, Guangfu Jin, Hongbing Shen.   

Abstract

To assess systematically whether potentially functional polymorphisms in DNA repair genes influence the clinical behavior of non-small-cell lung cancer (NSCLC), we examined the impact of a comprehensive panel of 218 signal nucleotide polymorphisms (SNP) in 50 candidate DNA repair genes on overall survival of NSCLC in a case-cohort of 568 lung cancer patients. SNPs associated with lung cancer prognosis primarily mapped to 14 genes in different repair pathways, and 6 SNPs were remained in the final model after multivariate stepwise Cox regression analysis: ATM rs189037; MRE11A rs11020802; ERCC2 rs1799793; MBD4 rs140693; XRCC1 rs25487, and PMS1 rs5742933. In the combined analysis of these 6 SNPs, an increasing number of unfavorable loci was associated with a poorer prognosis (P for trend: <0.0001) and patients having 2-4 unfavorable loci had a 1.99-fold elevated risk of death 95% confidence interval (CI) = 1.58-2.50, compared with those carrying 0-1 unfavorable loci, and this elevated risk was more evident among stages I-II patients (hazard ratio = 3.04, 95% CI = 1.86-4.98, P for heterogeneity: 0.07). Furthermore, a significant effect of SNPs in nucleotide excision repair pathway on lung cancer survival was observed among 185 stages III-IV patients treated with platinum-based chemotherapy without surgical operation: XPC rs2228000 (Ala499Val; P = 0.002) and ERCC1 rs11615 (Asn118Asn; P = 0.012). Our data indicate that potentially functional polymorphisms in DNA repair genes may serve as candidate prognostic markers of clinical outcome of NSCLC.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21739480     DOI: 10.1002/mc.20819

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  25 in total

1.  Polymorphisms in ERCC1 gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients.

Authors:  Xin Zhao; Zhiqiang Zhang; Yan Yuan; Xiaomei Yuan
Journal:  Tumour Biol       Date:  2014-05-24

2.  DNA repair genes polymorphism and lung cancer risk with the emphasis to sex differences.

Authors:  L Letkova; T Matakova; L Musak; M Sarlinova; M Krutakova; P Slovakova; E Kavcova; V Jakusova; M Janickova; A Drgova; P Berzinec; E Halasova
Journal:  Mol Biol Rep       Date:  2013-05-15       Impact factor: 2.316

3.  The study of the relation of DNA repair pathway genes SNPs and the sensitivity to radiotherapy and chemotherapy of NSCLC.

Authors:  Chunbo Wang; Huan Nie; Yiqun Li; Guiyou Liu; Xu Wang; Shijie Xing; Liping Zhang; Xin Chen; Yue Chen; Yu Li
Journal:  Sci Rep       Date:  2016-06-01       Impact factor: 4.379

4.  XRCC1 genetic polymorphisms and sensitivity to platinum-based drugs in non-small cell lung cancer: an update meta-analysis based on 4708 subjects.

Authors:  Ai-Qin Gu; Wei-Ming Wang; Wen-Yi Chen; Chun-Lei Shi; Jian-Hong Lu; Jun-Qing Han
Journal:  Int J Clin Exp Med       Date:  2015-01-15

5.  Functional variations in the ATM gene and susceptibility to differentiated thyroid carcinoma.

Authors:  Li Xu; Elaine Cristina Morari; Qingyi Wei; Erich M Sturgis; Laura S Ward
Journal:  J Clin Endocrinol Metab       Date:  2012-03-21       Impact factor: 5.958

Review 6.  The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.

Authors:  Yanlong Yang; Lei Xian
Journal:  Tumour Biol       Date:  2013-12-13

7.  Association between XRCC1 and XRCC3 polymorphisms and colorectal cancer risk: a meta-analysis of 23 case-control studies.

Authors:  Li Liu; Lin Miao; Guozhong Ji; Fulin Qiang; Zheng Liu; Zhining Fan
Journal:  Mol Biol Rep       Date:  2012-12-28       Impact factor: 2.316

8.  GLTSCR1, ATM, PPP1R13L and CD3EAP Genetic Variants and Lung Cancer Risk in a Chinese Population.

Authors:  Jiao-Yang Yin; Ye-Gang Ma; Ulla Vogel; Dong-Hui Liu; Zhen-Xiang Sun
Journal:  Curr Med Sci       Date:  2018-08-20

Review 9.  XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies.

Authors:  Jian Chen; Qing-wei Zhao; Gen-ming Shi; Lin-run Wang
Journal:  J Zhejiang Univ Sci B       Date:  2012-11       Impact factor: 3.066

10.  Association of the ATM gene polymorphisms with papillary thyroid cancer.

Authors:  Yulu Gu; Yaqin Yu; Lizhe Ai; Jieping Shi; Xiaoli Liu; Hui Sun; Yawen Liu
Journal:  Endocrine       Date:  2013-08-08       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.